May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Triamcinolone Plus Bevacizumab for Treatment of Refractory Diabetic Macular Edema
Author Affiliations & Notes
  • M. S. Folgosa
    Ophthalmology, Sch of Med of Rib Preto, Sao Paulo Univ, Americana, Brazil
  • R. A. Costa
    Ophthalmology, Eye Hospital of Araraquara, Araraquara, Brazil
  • D. R. Lucena
    Ophthalmology, Sch of Med of Rib Preto, Sao Paulo Univ, Americana, Brazil
  • I. U. Scott
    Ophthalmology, Departments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA., Hershey, Pennsylvania
  • R. Jorge
    Ophthalmology, Sch of Med of Rib Preto, Sao Paulo Univ, Ribeirão Preto, Brazil
  • Footnotes
    Commercial Relationships  M.S. Folgosa, None; R.A. Costa, None; D.R. Lucena, None; I.U. Scott, None; R. Jorge, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3515. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. S. Folgosa, R. A. Costa, D. R. Lucena, I. U. Scott, R. Jorge; Intravitreal Triamcinolone Plus Bevacizumab for Treatment of Refractory Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3515. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the short-term morphologic and visual acuity outcomes in a series of patients with refractory diffuse diabetic macular edema (DME) treated with one intravitreal injection of bevacizumab and one intravitreal injection of triamcinolone acetonide (both injections administered at the same sitting).

Methods: : Eight consecutive patients with DME unresponsive to macular laser grid photocoagulation (refractory diabetic macular edema) were assigned to receive an intravitreal injection of 1.25 mg/0.05ml of bevacizumab and an intravitreal injection of 2 mg/0.05ml of triamcinolone acetonide (both injections administered at the same sitting). Comprehensive ophthalmic evaluation was performed at baseline and at 1, 4, 8±1, and 12±2 weeks after treatment. Main outcome measures included central macular thickness measured with optical coherence tomography (OCT) and logMAR best-corrected visual acuity (BCVA).

Results: : Eight patients (8 eyes) completed the 12-week study period. The mean baseline central subfield thickness was 413.25 µm and the mean baseline logMAR BCVA was 0.715. A significant change from baseline in mean central subfield thickness (µm) was observed at week 1 (-69.38), week 4 (-123.38), and week 8 (-78.13) (p<0.05). A significant change from baseline in mean logMAR BCVA was observed at weeks 4 (-0.168) and 8 (-0.20) (p<0.05). There was no significant change from baseline in mean intraocular pressure (mmHg) at any study visit. No patient had observed cataract progression during the study.

Conclusions: : These results demonstrate that intravitreal injection of triamcinolone plus bevacizumab is associated with short-term improvements in central subfield thickness and visual acuity in eyes with refractory diffuse diabetic macular edema. Further studies are warranted to investigate longer-term outcomes in a larger series of eyes.

Keywords: macula/fovea • edema • diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×